Download PDF
Semin Neurol 2021; 41(05): 483-492
DOI: 10.1055/s-0041-1733787
Review Article

Diagnosis and Management of Status Epilepticus

Abrar O. Al-Faraj
1   Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
,
Myriam Abdennadher
2   Department of Neurology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts
,
Trudy D. Pang
3   Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Seizures are among the most common neurological presentations to the emergency room. They present on a spectrum of severity from isolated new-onset seizures to acute repetitive seizures and, in severe cases, status epilepticus. The latter is the most serious, as it is associated with high morbidity and mortality. Prompt recognition and treatment of both seizure activity and associated acute systemic complications are essential to improve the overall outcome of these patients. The purpose of this review is to provide the current viewpoint on the diagnostic evaluation and pharmacological management of patients presenting with status epilepticus, and the common associated systemic complications.

Keywords

causes of status epilepticus - treatment of status epilepticus - complications of status epilepticus - autoimmune encephalitis


Publication History

Article published online:
07 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 1990; 40 (05, Suppl 2): 9-13
    PubMedGoogle Scholar
  • 2 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56 (10) 1515-1523
    CrossrefPubMedGoogle Scholar
  • 3 Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40 (01) 120-122
    CrossrefPubMedGoogle Scholar
  • 4 Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol 2015; 14 (06) 615-624
    CrossrefPubMedGoogle Scholar
  • 5 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134 (Pt, 10): 2802-2818
    CrossrefPubMedGoogle Scholar
  • 6 Trinka E, Höfler J, Zerbs A. Causes of status epilepticus. Epilepsia 2012; 53 (Suppl. 04) 127-138
    CrossrefPubMedGoogle Scholar
  • 7 Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia 2001; 42 (08) 1031-1035
    CrossrefPubMedGoogle Scholar
  • 8 Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care 2014; 20 (03) 476-483
    CrossrefPubMedGoogle Scholar
  • 9 Leitinger M, Trinka E, Giovannini G. et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia 2019; 60 (01) 53-62
    CrossrefPubMedGoogle Scholar
  • 10 DeLorenzo RJ, Hauser WA, Towne AR. et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46 (04) 1029-1035
    CrossrefPubMedGoogle Scholar
  • 11 Hesdorber DC, Annegers JF, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998; 50 (03) 735-741
    CrossrefPubMedGoogle Scholar
  • 12 DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol 1995; 12 (04) 316-325
    CrossrefPubMedGoogle Scholar
  • 13 Gaspard N, Foreman BP, Alvarez V. et al; Critical Care EEG Monitoring Research Consortium (CCEMRC). New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015; 85 (18) 1604-1613
    CrossrefPubMedGoogle Scholar
  • 14 Costello DJ, Kilbride RD, Cole AJ. Cryptogenic new onset refractory status epilepticus (NORSE) in adults—Infectious or not?. J Neurol Sci 2009; 277 (1-2): 26-31
    CrossrefPubMedGoogle Scholar
  • 15 Hirsch LJ, Gaspard N, van Baalen A. et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018; 59 (04) 739-744
    CrossrefPubMedGoogle Scholar
  • 16 Glauser T, Shinnar S, Gloss D. et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr 2016; 16 (01) 48-61
    CrossrefPubMedGoogle Scholar
  • 17 Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 2004; 62 (10) 1743-1748
    CrossrefPubMedGoogle Scholar
  • 18 DeLorenzo RJ, Waterhouse EJ, Towne AR. et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998; 39 (08) 833-840
    CrossrefPubMedGoogle Scholar
  • 19 Hill CE, Blank LJ, Thibault D. et al. Continuous EEG is associated with favorable hospitalization outcomes for critically ill patients. Neurology 2019; 92 (01) e9-e18
    CrossrefPubMedGoogle Scholar
  • 20 Rossetti AO, Schindler K, Sutter R. et al. Continuous vs routine electroencephalogram in critically ill adults with altered consciousness and no recent seizure: a multicenter randomized clinical trial. JAMA Neurol 2020; 77 (10) 1-8
    CrossrefPubMedGoogle Scholar
  • 21 Brophy GM, Bell R, Claassen J. et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17 (01) 3-23
    CrossrefPubMedGoogle Scholar
  • 22 Treiman DM, Meyers PD, Walton NY. et al; Veterans Affairs Status Epilepticus Cooperative Study Group. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 1998; 339 (12) 792-798
    CrossrefPubMedGoogle Scholar
  • 23 Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249 (11) 1452-1454
    CrossrefPubMedGoogle Scholar
  • 24 Chamberlain JM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997; 13 (02) 92-94
    CrossrefPubMedGoogle Scholar
  • 25 Scott RC, Besag FMC, Neville BGR. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353 (9153): 623-626
    CrossrefPubMedGoogle Scholar
  • 26 Scheepers M, Scheepers B, Clarke M, Comish S, Ibitoye M. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy?. Seizure 2000; 9 (06) 417-422
    CrossrefPubMedGoogle Scholar
  • 27 Kapur J, Elm J, Chamberlain JM. et al; NETT and PECARN Investigators. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 2019; 381 (22) 2103-2113
    CrossrefPubMedGoogle Scholar
  • 28 Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia 2010; 51 (02) 251-256
    CrossrefPubMedGoogle Scholar
  • 29 Panebianco M, Marson A. Refractory status epilepticus. Essentials Neuroanesthesia 2017; 59: 309-314
    CrossrefPubMedGoogle Scholar
  • 30 Rossetti AO. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 2011; 10 (10) 922-930
    CrossrefPubMedGoogle Scholar
  • 31 Reznik ME, Berger K, Claassen J. Comparison of intravenous anesthetic agents for the treatment of refractory status epilepticus. J Clin Med 2016; 5 (05) 54
    CrossrefPubMedGoogle Scholar
  • 32 Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 33 Hanley DF, Kross JF. Use of midazolam in the treatment of refractory status epilepticus. Clin Ther 1998; 20 (06) 1093-1105
    CrossrefPubMedGoogle Scholar
  • 34 Naritoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology 2000; 54 (06) 1366-1368
    CrossrefPubMedGoogle Scholar
  • 35 Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E, Skaar DJ. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39 (01) 18-26
    CrossrefPubMedGoogle Scholar
  • 36 Gaspard N, Foreman B, Judd LM. et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013; 54 (08) 1498-1503
    CrossrefPubMedGoogle Scholar
  • 37 Hocker SE, Shorvon S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 2014; 83 (09) 866
    CrossrefPubMedGoogle Scholar
  • 38 Mahmoud SH, Rans C. Systematic review of clobazam use in patients with status epilepticus. Epilepsia Open 2018; 3 (03) 323-330
    CrossrefPubMedGoogle Scholar
  • 39 Fechner A, Hubert K, Jahnke K. et al. Treatment of refractory and superrefractory status epilepticus with topiramate: a cohort study of 106 patients and a review of the literature. Epilepsia 2019; 60 (12) 2448-2458
    CrossrefPubMedGoogle Scholar
  • 40 Rohracher A, Kalss G, Neuray C. et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: a single-center audit of 30 patients. Epilepsia 2018; 59 (May, Suppl 2): 234-242
    CrossrefPubMedGoogle Scholar
  • 41 Strzelczyk A, Steinig I, Willems LM. et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav 2017; 70 (Pt A): 177-181
    CrossrefPubMedGoogle Scholar
  • 42 Trinka E, Brigo F. Neurostimulation in the treatment of refractory and super-refractory status epilepticus. Epilepsy Behav 2019; 101 (Pt B) 106551
    CrossrefPubMedGoogle Scholar
  • 43 Muhlhofer WG, Layfield S, Lowenstein D. et al. Duration of therapeutic coma and outcome of refractory status epilepticus. Epilepsia 2019; 60 (05) 921-934
    CrossrefPubMedGoogle Scholar
  • 44 Schubert J, Brämer D, Huttner HB. et al; GENERATE and IGNITE Network. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm 2018; 6 (01) e514
    CrossrefPubMedGoogle Scholar
  • 45 Dubey D, Alqallaf A, Hays R. et al. Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol 2017; 74 (04) 397-402
    CrossrefPubMedGoogle Scholar
  • 46 Steriade C, Britton J, Dale RC. et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions. Epilepsia 2020; 61 (07) 1341-1351
    CrossrefPubMedGoogle Scholar
  • 47 Davis R, Dalmau J. Autoimmunity, seizures, and status epilepticus. Epilepsia 2013; 54 (Suppl. 06) 46-49
    CrossrefPubMedGoogle Scholar
  • 48 Probasco JC, Solnes L, Nalluri A. et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2017; 4 (04) e352
    CrossrefPubMedGoogle Scholar
  • 49 Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, Serrano-Castro PJ. Efficacy of antiepileptic drugs in autoimmune epilepsy: a systematic review. Seizure 2018; 59: 72-76
    CrossrefPubMedGoogle Scholar
  • 50 Shin YW, Lee ST, Park KI. et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord 2017; 11: 1756285617722347
    CrossrefPubMedGoogle Scholar
  • 51 Hantus S. Epilepsy emergencies. Continuum (Minneap Minn) 2016; 22 (1 Epilepsy): 173-190
    PubMedGoogle Scholar
  • 52 Linnoila J, Pittock SJ. Autoantibody-associated central nervous system neurologic disorders. Semin Neurol 2016; 36 (04) 382-396
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Kanter IC, Huttner HB, Staykov D. et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 2008; 49 (05) 914-920
    CrossrefPubMedGoogle Scholar
  • 54 Triplett J, Vijayan S, MacDonald A. et al. Fulminant anti-GAD antibody encephalitis presenting with status epilepticus requiring aggressive immunosuppression. J Neuroimmunol 2018; 323: 119-124
    CrossrefPubMedGoogle Scholar
  • 55 Hawkes MA, Hocker SE. Systemic complications following status epilepticus. Curr Neurol Neurosci Rep 2018; 18 (02) 7
    CrossrefPubMedGoogle Scholar
  • 56 Sutter R, Dittrich T, Semmlack S, Rüegg S, Marsch S, Kaplan PW. Acute systemic complications of convulsive status epilepticus—a systematic review. Crit Care Med 2018; 46 (01) 138-145
    CrossrefPubMedGoogle Scholar
  • 57 Vohra TT, Miller JB, Nicholas KS. et al; Neurological Emergencies Treatment Trials (NETT) Investigators. Endotracheal intubation in patients treated for prehospital status epilepticus. Neurocrit Care 2015; 23 (01) 33-43
    CrossrefPubMedGoogle Scholar
  • 58 Kennedy JD, Hardin KA, Parikh P, Li CS, Seyal M. Pulmonary edema following generalized tonic clonic seizures is directly associated with seizure duration. Seizure 2015; 27: 19-24
    CrossrefPubMedGoogle Scholar
  • 59 Baumann A, Audibert G, McDonnell J, Mertes PM. Neurogenic pulmonary edema. Acta Anaesthesiol Scand 2007; 51 (04) 447-455
    CrossrefPubMedGoogle Scholar
  • 60 Boggs JG, Painter JA, DeLorenzo RJ. Analysis of electrocardiographic changes in status epilepticus. Epilepsy Res 1993; 14 (01) 87-94
    CrossrefPubMedGoogle Scholar
  • 61 Eue S, Grumbt M, Müller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav 2009; 15 (04) 467-469
    CrossrefPubMedGoogle Scholar
  • 62 Stöllberger C, Wegner C, Finsterer J. Seizure-associated takotsubo cardiomyopathy. Epilepsia 2011; 52 (11) e160-e167
    CrossrefPubMedGoogle Scholar
  • 63 Lemke DM, Hussain SI, Wolfe TJ. et al. Takotsubo cardiomyopathy associated with seizures. Neurocrit Care 2008; 9 (01) 112-117
    CrossrefPubMedGoogle Scholar
  • 64 Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010; 18 (03) 322-324
    CrossrefPubMedGoogle Scholar
  • 65 Corbellini AB, Hristova V, Garcia A. et al. Cardioembolic ischemic stroke in the context of atrial fibrillation after low-dose intravenous infusion of lacosamide: case report and literature review. Eur J Neurol 2019; 26 (s1): 406-407
    PubMedGoogle Scholar
  • 66 Miller MA, Forni A, Yogaratnam D. Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital. Ann Pharmacother 2008; 42 (10) 1502-1506
    CrossrefPubMedGoogle Scholar
  • 67 Semmlack S, Tschudin-Sutter S, Widmer AF. et al. Independent impact of infections on the course and outcome of status epilepticus: a 10-year cohort study. J Neurol 2016; 263 (07) 1303-1313
    CrossrefPubMedGoogle Scholar
  • 68 Belluzzo M, Furlanis G, Stragapede L, Monti F. Role of comorbidities and in-hospital complications in short-term status epilepticus outcome. Clin Neurol Neurosurg 2017; 154: 13-18
    CrossrefPubMedGoogle Scholar
  • 69 Scholtes FB, Renier WO, Meinardi H. Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia 1994; 35 (05) 1104-1112
    CrossrefPubMedGoogle Scholar
  • 70 Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994; 35 (01) 27-34
    CrossrefPubMedGoogle Scholar
  • 71 Claassen J, Lokin JK, Fitzsimmons B-FM, Mendelsohn FA, Mayer SA. Predictors of functional disability and mortality after status epilepticus. Neurology 2002; 58 (01) 139-142
    CrossrefPubMedGoogle Scholar